Genelux's cancer treatment, Olvi-Vec, shows promise after positive FDA meeting and successful trials.

Genelux Corporation has concluded a productive meeting with the FDA regarding its cancer treatment, Olvi-Vec, for ovarian cancer, potentially leading to traditional approval if clinical benefits are shown. In separate trials for small cell lung cancer, Olvi-Vec demonstrated a 71% disease control rate and was well-tolerated, showing promise for treating various cancers with high unmet medical needs.